Dr. Yu’s laboratory studies the role of cytokine growth factor signaling in cardiovascular homeostasis, injury repair, and regeneration. Specifically, the laboratory has devised novel models, molecular tools, and pharmacologic probes for examining the function of bone morphogenetic protein (BMP), activin, growth and differentiation factor (GDF), and transforming growth factor-beta (TGF-b) signaling in cardiovascular and musculoskeletal development and function. A major focus of his laboratory’s work is to discern how BMP/TGF-β signaling achieves spatio-temporal and functional specificity for developmental patterning, and to modulate the tissue-specific consequences of inflammation and injury. Dr. Yu’s clinical and translational interests including pulmonary vascular disease, cardiovascular rheumatology, and fibrodysplasia ossificans progressiva
Dr. Paul Yu is Director of the Cardiovascular Research Center (CVRC) at Massachusetts General Hospital, recipient of the Charles Addison Sanders and Elizabeth Ann Sanders Endowed Chair, Associate Professor of Medicine at Harvard Medical School, and Physician in Cardiovascular Medicine at Massachusetts General Hospital (MGH). Dr. Yu completed his AB in Philosophy and a BS in Biological Sciences at Stanford University, MD and PhD (Immunology) degrees at Duke University, completed Internal Medicine residency at UCSF, clinical and research fellowships in Cardiovascular Disease at MGH, and is board certified in Cardiovascular Medicine. Following a postdoctoral fellowship in cardiovascular biology with Dr. Kenneth Bloch, Dr. Yu established his independent laboratory at MGH in 2007, joined a collaborative basic and translational research effort in pulmonary arterial hypertension at BWH in 2011, and has returned to MGH in 2022 as Director of the CVRC.
More information on Dr. Yu’s research program.